Trial reportESMO open2026
Overall survival from the open-label phase II trial of palbociclib in patients with advanced well-differentiated/dedifferentiated liposarcoma.
Trial report in ESMO open, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Transcriptional Heterogeneity in Dedifferentiated Liposarcoma Reveals Distinct Cell-Cycle Subtypes.Annals of surgical oncology · 2026Article
- A Case Report: Retroperitoneal dedifferentiated liposarcoma with heterologous myogenic differentiation and testicular metastasis.Frontiers in oncology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
Abstract
backgroundWell-differentiated (WD) and dedifferentiated (DD) liposarcomas (LPS) are characterized by cyclin-dependent kinase (CDK)4 and mouse double minute 2 homolog (MDM2) amplification. Palbociclib, a selective CDK4/6 inhibitor, demonstrated promising activity in prior phase II trials and is included in the National Comprehensive Cancer Network Compendium for LPS. However, long-term overall survival (OS) data remain limited. PATIENTS AND
methodsPatients with advanced WD/DD LPS were enrolled in two non-randomized phase II trials. Cohort A received palbociclib 200 mg (14 days on, 21-day cycle); cohort B received 125 mg (21 days on, 28-day cycle). Kaplan-Meier methods were used to estimate progression-free survival (PFS) and OS. Baseline factors and subsequent anticancer therapies were evaluated for association with outcomes.
resultsAmong 90 patients, 88 were assessable for PFS. Median follow-up was 3.12 years (cohort A) and 2.59 years (cohort B). Median PFS was 4.2 and 4.1 months, and median OS was 26.0 and 24.2 months in cohorts A and B, respectively. One- and two-year OS rates exceeded 70% and 50%, respectively, across cohorts. Patients with pure WD histology (n = 15) had longer PFS (hazard ratio 0.53, P = 0.037) but no OS difference. Cadherin 18 (CDH18) expression on baseline tumor tissue was associated with improved PFS (P = 0.007) and OS (P = 0.003). After treatment, 39% underwent surgery and 46% received additional systemic therapy.
conclusionsThis study provides the longest prospective OS data for palbociclib in WD/DD LPS. CDK4/6 inhibition remains a relevant treatment option, especially for patients unsuitable for cytotoxic therapy. CDH18 expression was associated with clinical outcomes and represents an exploratory biomarker signal that warrants independent validation in future prospective, biomarker-focused studies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.